Johnson & Johnson reported Q3 revenue of $25.4 billion, driven by a 7.9% operational growth in its Innovative Medicine segment, while its MedTech division grew only 2.5%. The company raised its 2026 revenue guidance slightly to $101.2 billion, up from $101.1 billion previously. TREMFYA sales of $2.4 billion helped offset declines in STELARA, supported by strong Phase 3 clinical data. However, challenges remain in the MedTech segment, especially in Surgery, Abiomed, and international markets. The 2027 outlook faces potential EPS dilution from acquisitions, but overall the company maintains a positive outlook with a hold recommendation.
Johnson & Johnson shares are trading at USD 274.35 with a 1.22% gain as of Oct 29, 2026, 14:51 WIB on Pluang. Despite the strong Q3 growth and raised 2026 revenue guidance, the platform shows a majority of sell orders at 78%, indicating cautious sentiment among investors. The stock remains near its 52-week high of USD 278.43, reflecting resilience amid mixed segment performance and future earnings concerns.
Pomerantz LLP is investigating Johnson & Johnson for potential securities fraud following the company's Q3 2026 report, which showed net earnings of $210 million due to large charges from talc litigation settlements. The MedTech segment's revenue gro...
Medtronic increased its quarterly dividend to $0.72 per share, marking a 1.4% raise and extending its dividend increase streak to 49 years. While this steady growth ensures a reliable 2.95% yield, it trails behind faster-growing peers like Abbott and...
Johnson & Johnson and Procter & Gamble are highlighted as two safe S&P 500 dividend stocks ideal for retirees seeking reliable income. Johnson & Johnson has raised its dividend for 64 consecutive years, supported by strong free cash flow and diverse ...
New Phase 3 PROTEUS substudy results show that adding apalutamide plus androgen deprivation therapy (ADT) before and after surgery reduces the risk of prostate cancer recurrence or death by 62% compared to surgery alone in high-risk localized or loca...
